A pproximately 6% of all American adults suffer from coronary artery disease (CAD), with estimated total annual costs in excess of $200 billion.
Over the past 2 decades, numerous clinical trials have compared the clinical outcomes of PCI and CABG for patients with multivessel CAD. In general, these studies have demonstrated similar short-and long-term mortality with either procedure (with the exception of diabetic patients) but substantial advantages of CABG in terms of angina relief and the need for subsequent revascularization procedures. [2] [3] [4] [5] [6] [7] [8] Economic evaluations performed in both the balloon angioplasty and bare metal stent eras have consistently demonstrated early cost savings with PCI but similar long-term costs for the 2 strategies. 7, 9, 10 Clinical Perspective on p 1157
The most recent study to compare PCI with CABG in a broad population was the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. 11 In contrast to previous studies, SYNTAX included patients with more complex CAD (3-vessel and left main disease), had few exclusion criteria, and used drug-eluting stents (DES) for all PCI procedures. At the 5-year followup, SYNTAX demonstrated that CABG was associated with a lower rate of the composite of cardiovascular death, myocardial infarction (MI), stroke, or repeat revascularization compared with DES-PCI, driven mainly by reductions in nonfatal MI and repeat revascularization. 12 However, DES-PCI was associated with a lower rate of stroke in the overall population and similar overall clinical outcomes in certain patient subsets. 12, 13 Given the current economic challenges facing virtually all healthcare systems, understanding both the long-term clinical benefits and cost-effectiveness of these alternative revascularization strategies is critical for clinical guideline development and healthcare policy. We therefore performed a prospective health economic evaluation alongside the SYNTAX trial. Although the SYNTAX trial included only a 5-year follow-up, we used disease simulation techniques to extrapolate the 5-year trial results to a lifetime horizon.
Methods
The design and methods of the SYNTAX trial have been described previously. 11, 12, 14 Between March 2005 and April 2007, 1800 patients with 3-vessel or left main CAD without recent MI who were considered equally suitable for PCI with DES and CABG by both a cardiac surgeon and an interventional cardiologist were randomized to either procedure. CABG was performed using standard techniques, and PCI procedures used paclitaxel-eluting stents (TAXUS Express, Boston Scientific, Natick, MA). The institutional review board at each participating site approved the protocol, and all patients provided written informed consent. The trial complies with the Declaration of Helsinki and is registered at the National Institutes of Health Web site (http:// www.clinicaltrials.gov; identifier, NCT00114972).
Estimation of Medical Care Costs
Costs for the initial hospitalization and the 5-year follow-up period were assessed by a combination of resource-based and event-based methods as described below. These methods were virtually identical to those used for a recent health economic assessment of DES-PCI versus CABG among diabetic patients. 15 To maintain consistency with that previous report, all costs were assessed from the perspective of the US healthcare system and are reported in 2010 US dollars.
Procedural Costs
Detailed resource use was recorded for each initial and any subsequent revascularization procedures, and the cost for each item was estimated on the basis of its mean hospital acquisition cost at 3 surveyed US hospitals. Each DES was assigned a cost of $1500. Costs of antithrombotic therapy were based on the current wholesale acquisition cost obtained from Micromedex Red Book. 16 Costs for additional disposable equipment, overhead, depreciation of the cardiac catheterization laboratory and operating room, and nonphysician personnel were estimated using data from the microcost accounting systems of Saint Luke's Mid America Heart Institute and adjusted for observed procedure duration. For the purposes of this report, initial and planned staged PCI procedures were combined for the calculation of index resource use and cost.
Postprocedural Hospitalization Costs
Postprocedural costs for each initial hospitalization were estimated from regression models based on SYNTAX-eligible patients who underwent either PCI (n=113 921) or CABG (n=43 866) and whose data were included in the 2010 Medicare Provider and Review database. Hospital charges were converted into costs using hospital-and cost center-specific cost-to-charge ratios. 17, 18 Linear regression models were then developed, with total hospitalization costs used as the outcome and sociodemographic factors, comorbidities, and in-hospital complications (identified on the basis of International Classification of Diseases, Ninth Revision codes) as predictors ( Table I in the onlineonly Data Supplement). Because of substantial variability in length of stay for revascularization procedures across the enrolling countries, length of stay was not included as a predictor in these models. The final models for PCI and CABG were then used to predict nonprocedural costs for each initial hospitalization and any subsequent hospitalizations that involved coronary revascularization. To avoid double counting of procedural costs, the intercept for each model was adjusted to remove the costs directly related to the revascularization procedures.
For follow-up cardiovascular hospitalizations that did not involve a revascularization procedure, Medicare severity-diagnosis-related groups were assigned on the basis of the primary indication for hospitalization and procedures performed during that admission. Costs were then assigned on the basis of mean 2010 Medicare reimbursement rates for the Medicare severity-diagnosis-related group obtained from the Medicare Part A data files.
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Physician Costs
Physician fees for PCI and CABG procedures (including those for the primary surgeon, surgical assistant, and anesthesiologist) were based on the 2010 national Medicare fee schedule. Non-procedure-related physician fees for revascularization-related hospitalizations were estimated for US patients on the basis of postprocedural intensive care unit and non-intensive care unit lengths of stay and Medicare payment rates. For non-US patients, postprocedural length of stay after CABG and PCI was estimated from regression models developed with 2010 Medicare Provider and Review data and the same covariates used in the cost models (Table II in the online-only Data  Supplement) , along with PCI-and CABG-specific ratios of intensive care unit versus total postprocedural length of stay estimated from the trial data for US patients. Physician costs for all other hospitalizations were estimated as a percentage of hospital costs according to the Medicare severity-diagnosis-related group.
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Outpatient Costs
Costs for outpatient visits, tests, procedures, and inpatient rehabilitation and skilled nursing facility days were estimated from 2010 Medicare reimbursement rates. Outpatient medication use was assessed at each follow-up visit, and costs were assigned using the most current average wholesale prices from Micromedex Red Book.
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Quality of Life
Quality of life was assessed directly from patients at baseline and at 1, 6, 12, 36, and 60 months with the EuroQOL (EQ-5D [EuroQOL 5 dimensions questionnaire]) health status instrument and converted to utility weights (range, 0-1) with the use of an algorithm developed from the US population. September 30, 2014
Statistical Analysis
To account for the slightly higher withdrawal rate among patients assigned to CABG, a modified intention-to-treat (mITT) population was used as the primary population for economic analysis. This population was defined as all randomized patients who underwent ≥1 initial revascularization procedure (n=1766), with patients categorized according to their assigned treatment. Because virtually all of the patients who did not undergo revascularization withdrew from the trial within the first 6 months of follow-up, the mITT approach is preferred because it includes initial revascularization costs for all patients while yielding survival estimates that are virtually identical to those for an ITT analysis using censored data. A secondary analysis used the per-protocol population and included only those patients who underwent the assigned revascularization procedure (n=1739).
Categorical data are reported as frequencies, and continuous data are reported as mean±SD. Discrete variables were compared by use of Fisher exact tests. Normally distributed continuous variables were compared by use of Student t tests, and nonnormally distributed data were compared by use of the Wilcoxon rank-sum test. Treatment effects from Poisson regression models were used for the comparison of hospitalization rates. Kaplan-Meier estimates and log-rank tests were used for the comparison of 5-year clinical events. Cost data are reported as both mean and median values and were compared by use of t tests. 23 Confidence intervals (CIs) for the differences in costs between treatment groups were obtained by bootstrapping (1000 replicates). 24 Quality-adjusted life expectancy was calculated for each patient as the time-weighted average of his/her utility values. The midpoint between assessments was used as the transition between health states, starting at the 30-day visit. Missing utility values were estimated from multiple imputation, taking into account baseline patient characteristics, clinical events including hospitalizations, and previous utility values.
In-Trial Analysis of Costs, Life-Years, and QualityAdjusted Life-Years
Because not all patients had complete 5-year follow-up data, methods for the analysis of censored data were used to obtain estimates of cumulative costs and quality-adjusted life-years (QALY) at each follow-up time point. 25 We used Kaplan-Meier methods to estimate survival at each follow-up time point, and life expectancy differences were estimated as the area between the 2 survival curves. For costs, an inverse probability-weighted estimator was applied whereby the time axis was divided into 3-month intervals, and costs for each interval were estimated as the observed costs during the interval for patients with complete data divided by the probability of not being censored within the interval. Similar methods were applied to estimate QALYs. The bootstrap method was used to calculate the confidence limits for the mean cumulative cost, life-year, and QALY estimates for each treatment group, as well as the difference between groups. 
Cost-Effectiveness
The cost-effectiveness of CABG versus PCI was assessed over a lifetime horizon with QALYs used as the measure of health benefit for the primary analysis and life-years for secondary analyses. 26 Costs, lifeyears, and QALYs were discounted at 3%/y for all cost-effectiveness calculations. 27 The lifetime analyses were based on a combination of observed in-trial cost and quality-of-life data and projections of posttrial costs, life expectancy, and quality-adjusted life expectancy obtained from a Markov disease simulation model. In this model, each surviving patient was assumed to face a monthly risk of death, with estimates of this risk based on the age-, sex-and race-specific risk of death obtained from US life tables, which were calibrated to match the observed 5-year mortality for the SYNTAX PCI population. 15, 28 For the CABG group, an additional multiplicative factor was applied to project the benefit of CABG versus PCI on mortality. This multiplier was based on the hazard ratio (HR) derived from an analysis of all-cause mortality from the SYNTAX patients. In a sensitivity analysis, the separate impact of nonfatal MI and stroke on long-term mortality was taken into account. For these secondary analyses, HRs were obtained from a Cox proportional hazards regression model fit to the trial data in which nonfatal MI and stroke were each modeled as time-dependent covariates and baseline characteristics (age, sex and diabetes mellitus) and treatment group were included as fixed covariates. Patient-level costs and utility weights for each projected year of life beyond the trial observation period were derived from regression models developed from the in-trial data (Tables III and IV in the online-only Data Supplement).
Three sets of analyses were performed on the basis of alternative assumptions about the duration of the prognostic benefit of CABG relative to PCI. The base-case analysis assumed that the benefit of CABG tapered in a linear fashion from year 5 to 10 and that there were no prognostic differences between PCI and CABG beyond year 10 (ie, HR=1 after year 10). In sensitivity analyses, we assumed either that the prognostic benefits of CABG would remain constant from year 5 to 10 with no benefit of CABG after 10 years or that there would be no further prognostic benefit of CABG beyond the 5-year trial observation period (ie, HR=1 after year 5).
Bootstrap methodology (1000 replicates) was used to estimate uncertainty in the joint distribution of lifetime cost, life-years, and QALYs for each treatment group. To maintain consistency of the within-trial and posttrial CABG effect within each bootstrap sample, the HRs for the effect of CABG versus PCI on mortality were reestimated for each bootstrap replicate. All analyses were performed with SAS 9.3 (SAS Institute, Cary, NC.).
Results
Patient Population
Overall, a total of 1800 patients with 3-vessel or left main CAD were randomized to either CABG (n=897) or PCI (n=903). Of these, 27 patients assigned to CABG and 7 patients assigned to PCI did not undergo any revascularization procedure and were excluded from the primary mITT population for this economic analysis (Figure 1 ). Baseline characteristics for the mITT population are summarized in Table 1 . There were no significant differences in any observed characteristics between the CABG and PCI groups. Of the mITT patients, 13.6% were enrolled in the United States, 39% had left main CAD, and the median follow-up was 60 months.
Initial Treatment Costs
Among patients assigned to PCI, 98.8% underwent PCI and 1.2% underwent CABG. Among patients assigned to CABG, 98.2% underwent CABG and 1.8% underwent PCI. Resource use for the initial revascularization procedures is summarized in Table 2 (per-protocol population). In the PCI group, 13.6% underwent staged procedures, with 13.5% requiring 2 procedures and 0.1% requiring 3 procedures. On average, the initial PCI procedure required 2.1 guiding catheters, 3.5 guidewires, 3.7 angioplasty balloons, and 4.5 DES. Although procedure duration was longer for CABG, initial procedure costs were ≈$3500 lower with CABG compared with PCI ($8504 versus $11 919; P<0.001) owing to the higher costs associated with consumable resources (including stents) for the PCI group. For the mITT population, the difference in initial procedural costs was slightly smaller ($8482 versus $11 866; P<0.001) as a result of the small proportion of patients who crossed over to the alternative treatment strategy.
Clinical events, resource use, and costs during the initial hospitalization are summarized in Table 3 . Postprocedural hospital costs were greater for the CABG group than the PCI group ($19 511 versus $8785; P<0.001), as were physician fees ($5100 versus $2315; P<0.001). As a result, total initial hospitalization costs were ≈$10 000 per patient higher in the CABG group than in the PCI group ($33 190 versus $23 154; P<0.001).
Follow-Up Resource Use and Costs
Follow-up clinical outcomes, resource use, and costs are summarized in Table 4 . During each year of follow-up, the annual rates of repeat revascularization, diagnostic catheterization, and hospitalization and their associated costs were higher for the PCI group compared with the CABG group. In addition, costs for outpatient services and medications were consistently higher for patients assigned to initial PCI versus CABG. Rehabilitation costs were greater in the CABG group in the first year and were similar between treatments in the subsequent years. As a result, the difference in cumulative medical care costs between the CABG and PCI narrowed from $10 036 after the index hospitalization to $5619 after 5 years of follow-up (Table 5 and Figure 2 ).
Utility Weights and QALYs
Compared with baseline, utility weights improved substantially for both treatment groups over the course of the trial (Table V in the online-only Data Supplement). At the 1-month followup, utility weights were significantly lower after CABG than PCI (0.77 versus 0.85; P<0.001), reflecting the longer recovery period after CABG. This early utility benefit of PCI was no longer apparent at 6 months, however. As a result of the early difference in favor of PCI, cumulative QALYs were lower with CABG than with PCI through 3 years of follow-up (Table 5) . By the end of year 5, however, both life expectancy (4.70 versus 4.60 years) and quality-adjusted life expectancy (3.91 versus 3.87 QALYs) were greater with CABG than with PCI. Results from the lifetime cost-effectiveness analyses are summarized in Table 6 . On the basis of the observed 5-year results, the estimated mortality HR for CABG versus PCI was 0.80 (95% CI, 0.61-1.05). When these results were used to project clinical and economic outcomes beyond the trial period (Figure 3) , we estimated that CABG would be associated with lifetime incremental costs of $5081 (95% CI, 1802-8241) compared with PCI, together with a gain in life expectancy of 0.412 years (95% CI, −0.060 to 0.831) and a gain in quality-adjusted life expectancy of 0.307 QALYs (95% CI, −0.105 to 0.378).
The resulting incremental cost-effectiveness ratio (ICER) for CABG versus PCI was $16 537 per QALY gained, with 84.7% of bootstrap replicates falling below a societal willingness-to-pay threshold of $50 000 per QALY (Figures 4 and 5  and Table 6 , row 1). When outcomes were assessed in lifeyears, CABG was associated with an ICER of $12 329 per lifeyear gained (Table 6 , row 2). When the analysis also accounted for the prognostic impact of nonfatal MI and stroke, the benefit of CABG increased modestly to 0.338 QALYs, and the ICER improved to $15 758 per QALY gained, with 87.7% of bootstrap replicates falling below a societal willingness-to-pay threshold of $50 000 per QALY ( Figure 5 and Table 6 , row 4).
These results were robust across a wide range of alternative assumptions about the duration and magnitude of the benefit of CABG over PCI on both survival and costs beyond the time frame observed in the trial. When we assumed that the benefits of CABG would remain constant from year 5 to 10 with no further benefit beyond 10 years, the ICER for CABG versus PCI improved to $10 695 per QALY gained. Under the conservative assumption of no benefit of CABG beyond the 5-year trial period, the ICER increased to $27 485 per QALY gained, with 74.8% of the bootstrap replicates below the threshold of $50 000 per QALY gained. Results were also similar when the analysis incorporated the prognostic impact of nonfatal MI and stroke or when effectiveness was expressed in life-years rather than QALYs (Tables VII and  VIII in the online-only Data Supplement).
Subgroup Analyses
Results from prespecified subgroup analyses are summarized in Table IX in the online-only Data Supplement (observed 5-year results) and Table 7 (lifetime projections). For most subgroups, the results were consistent with those of the overall trial population, albeit with greater uncertainty resulting from the reduced sample sizes. Two subgroups had results that differed substantially from those of the overall trial, however. For patients with less complex coronary anatomy (SYNTAX score ≤22), PCI was projected to increase quality-adjusted life expectancy and to reduce costs compared with CABG. For this subgroup, the probability that CABG would be economically attractive at an ICER of $50 000 per QALY was only 18.3%. In contrast, for patients with SYNTAX scores of 23 to 32 and ≥33, the ICERs for CABG versus PCI were $36 790 and $8219 per QALY gained, respectively. PCI was also projected to be an economically dominant strategy for patients with left main CAD, whereas CABG appeared to be highly economically attractive compared with PCI for patients with 3-vessel disease (ICER, $4905 per QALY gained). For all other patient subgroups, CABG was projected to be economically attractive compared with PCI with ICERs <$35 000 per QALY gained. Results for subgroups were largely unchanged under alternative assumptions about the duration and magnitude of the benefit of CABG over PCI and when we considered the impact of nonfatal MI and stroke on mortality (Table VII and IX in the online-only Data Supplement).
Impact of Stent Pricing and Productivity Losses
Because DES prices in the United States continue to decrease each year, we performed a sensitivity analysis of the acquisition cost of DES ( Figure 6 ). Although the ICER for CABG versus PCI increased as the acquisition cost of DES decreased, even at a DES price of $0, the ICER for CABG versus PCI in the overall study population remained <$40 000 per QALY gained. When this sensitivity analysis was repeated within strata according to SYNTAX score, only the intermediate SYNTAX score tertile was sensitive to stent price (Table X in the online-only Data Supplement). For patients with a SYNTAX score ≤22, the PCI strategy remained economically attractive unless the stent price exceeded $4880 per stent, whereas for patients with a SYNTAX score ≥33, CABG remained economically attractive at all stent prices. Among patients with SYNTAX scores between 23 and 32, however, the ICER for CABG versus PCI remained <$50 000 per QALY gained only if the stent price was >$1195.
Finally, we performed a sensitivity analysis to assess the impact of productivity loss on the cost-effectiveness of CABG versus DES-PCI. Because no data on employment were collected from the SYNTAX trial patients, we used several external sources to estimate the proportion of patients used at baseline, the timing of return to work according to the type of revascularization procedure, and the average earning for a US worker. 9, 29 With incorporation of these factors, the cost difference between the treatments increased by ≈$1000 for the overall population, reflecting the higher productivity loss with CABG compared with PCI, but the ICER for CABG versus PCI remained <$20 000 per QALY gained (Table XI in the online-only Data Supplement). When this additional analysis was repeated for subgroups according to SYNTAX score tertile and the left main or 3-vessel disease subgroups, the outcomes were similar to the main analyses that did not incorporate productivity losses.
Discussion
SYNTAX is the first study to directly compare the long-term clinical and economic outcomes of DES-PCI and CABG for patients with 3-vessel or left main CAD. Thus, this economic substudy provides a number of critical insights into the optimal revascularization strategy for such patients. First, we found that despite substantially higher procedural costs, DES-PCI is substantially less costly than CABG in the short term. Second, although CABG was associated with improved clinical outcomes and reduced follow-up resource use, cumulative costs remained lower with DES-PCI (by ≈$5000 per patient) at 5 years and over a lifetime horizon. Third, although differences in life expectancy and quality-adjusted life expectancy were small over the 5-year time frame of the trial (0.100 years and 0.044 QALYs, respectively), the incremental life expectancy and QALY gains with CABG increased considerably 30, 31 Moreover, although SYNTAX did not demonstrate a statistically significant difference in 5-year mortality between CABG and DES-PCI, these main findings were robust both to stochastic uncertainty analyses (ie, bootstrapping) and to a variety of alternative assumptions about the durability of benefit, the prognostic impact of nonfatal events, and stent pricing. In general, the economic outcomes of the SYNTAX trial mirrored the clinical results.
Although the results of the overall trial were robust, subgroup analyses demonstrated several key cohorts with results that diverged from those of the main SYNTAX population. Specifically, among patients with left main disease or SYNTAX score ≤22, DES-PCI was projected to be an economically dominant strategy that resulted in similar or greater quality-adjusted life expectancy and lower lifetime costs compared with CABG. Although these results were not definitive (mainly because of uncertainty with respect to long-term survival differences), these findings suggest that DES-PCI may be the preferred strategy for patients with less anatomically complex CAD on both clinical and economic grounds. In contrast, among patients with 3-vessel disease or with anatomic SYNTAX scores ≥32, CABG was strongly favored on economic grounds, with ICERs <$10 000 per QALY gained and a <6% probability that the ICER exceeds $50 000 per QALY gained. Although subgroup analyses are typically considered hypothesis generating when interpreting clinical trial results, cost-effectiveness analysis is driven by measures of absolute cost and benefit that may be more susceptible to meaningful interactions. Thus, subgroup effects in cost-effectiveness analysis are frequently considered to be valid considerations for guideline development and healthcare policy, particularly when the results are supported by appropriate uncertainty analyses and are consistent with the underlying pathophysiology. 32 The finding that our results were only minimally sensitive to stent pricing was somewhat surprising. Although device prices are commonly perceived to be an important determinant of their cost-effectiveness, 33 when comparing DES-PCI versus CABG, we found that the major determinant of costeffectiveness was the gain in life expectancy rather than the cost difference per se. Consequently, there was no device cost at which DES-PCI would be economically attractive compared with CABG either in the overall trial population or in patients with a high SYNTAX score. Only among patients with an intermediate SYNTAX score (in whom the gain in quality-adjusted life expectancy with CABG was minimal) would DES-PCI become the economically preferred therapy if the device cost were reduced by ≈20% from current levels. 
Comparison With Previous Studies
These findings contrast with those from our previous costeffectiveness analysis of DES-PCI versus CABG based on the 1-year SYNTAX trial results in which we reported that DES-PCI was an economically dominant strategy. 34 Compared with that previous report, the initial cost difference in favor of DES-PCI has increased from ≈$5000 to ≈$10 000 per patient, changes driven largely by the substantial reduction in DES prices over the last 4 to 5 years (from $2200 to $1500 per stent). Another important difference between the 2 studies is the cost difference in the first year of follow-up, which decreased from ≈$2300 in the original study to ≈$1700 in the present study, mainly as a result of reductions in the cost of dual antiplatelet therapy with the approval of generic clopidogrel. The most important difference between the 2 studies was that in the 1-year study, quality-adjusted life expectancy favored DES-PCI (reflecting the early quality-of-life and survival advantage), whereas in the present study, qualityadjusted life expectancy was greater with CABG. These differences highlight the importance of basing policy decisions on clinical trials with sufficiently long follow-up to allow prognostically important benefits to emerge. Although many third-party payers in the United States are more concerned with a 1-to 3-year time horizon than a lifetime horizon, the results of our study demonstrate how analyses that focus solely on short-term economic and clinical outcomes may fail to incorporate the full benefits of the more effective therapy and arrive at misleading conclusions.
Numerous previous studies have sought to evaluate the relative cost-effectiveness of PCI versus CABG for patients with multivessel CAD. 7, 9, 15, 28, [35] [36] [37] [38] [39] However, most of these studies are limited by relatively short follow-up durations 7, 34, 36, 39 or Costs and QALYs are discounted at 3% per year. Δ indicates difference between CABG and PCI groups; CABG, coronary artery bypass grafting; CI, confidence interval; ICER, incremental cost-effectiveness ratio for coronary artery bypass grafting versus percutaneous coronary intervention; LM, left main; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-year gained; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery. *Probability that CABG is the preferred strategy at a societal ICER of $50 000 per QALY gained. by focusing solely on costs without performance of a formal cost-effectiveness analysis. 35 In addition, no studies to date have examined the cost-effectiveness of PCI versus CABG for patients with left main disease. With respect to methodology and duration of follow-up, our study is most comparable to economic evaluations performed alongside the Bypass Angioplasty Revascularization Investigation (BARI) and Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trials. In BARI, the ICER for CABG versus balloon angioplasty was ≈$14 000 per life-year gained over a 12-year follow-up period, 28 a result that is quite similar to that from the SYNTAX trial. In contrast to SYNTAX, however, BARI found that for patients with 3-vessel CAD, costs were actually lower with CABG than PCI over 5 years of followup. 9 It is likely that these differences between trials reflect the much lower rate of repeat revascularization procedures after PCI seen in SYNTAX compared with BARI with the introduction of effective DES (26% versus 54%). 3, 12 FREEDOM, the only other trial to compare the costeffectiveness of PCI and CABG in the DES era, demonstrated that for patients with diabetes mellitus and multivessel CAD, CABG is highly cost-effective compared with DES-PCI, with an ICER of ≈$8000 per QALY gained. 15 Although these overall results are relatively similar to those seen in SYNTAX, in FREEDOM, CABG was economically attractive across the full range of SYNTAX scores, whereas in SYNTAX, CABG was attractive only for patients with moderate to high degrees of angiographic complexity (SYNTAX score >22). These findings may relate to underlying differences in atherosclerosis between patients with versus without diabetes mellitus or may reflect the fact that diabetic patients often have additional conditions (eg, renal dysfunction, peripheral artery disease) that confer higher cardiovascular risk. 13 Of note, patients with left main coronary disease were not studied in either BARI or FREEDOM.
Limitations
Our study has several important limitations. First, our economic analysis was performed from the perspective of the US healthcare system, although the SYNTAX trial enrolled patients from 18 countries. To address this issue, costs associated with the index procedures were estimated from detailed resource use, which would not be expected to differ by geography. Because hospital length of stay differs across countries, all other costs were estimated using methods that are independent of length of stay and depend only the assumption that clinical outcomes and procedural complications are similar across healthcare systems. 40 Although it would have been possible to exclude all non-US patients from our analysis, this would have markedly reduced our sample size and added considerable variability to the results. It is nonetheless reassuring that our main results were consistent between patients enrolled in the United States compared with other countries.
Second, the need for lifetime extrapolations required several assumptions about the impact of CABG on long-term survival, healthcare costs, and quality of life. To the greatest extent possible, we used empirical data from the trial to inform these assumptions and examined the impact of plausible alternatives in sensitivity analyses, the results of which were similar to the result of our primary results. Third, all DES patients in the SYNTAX trial were treated with paclitaxel-eluting DES. Recently, second-generation DES have demonstrated lower rates of MI, target vessel revascularization, and stent thrombosis compared with first-generation DES. 41 Therefore, the cost results of the present study may not be generalizable to patients treated with second-generation DES. It is unlikely that the main results of our analysis would change substantially with use of second-generation DES, however, because there is no evidence that these devices reduce mortality compared with the paclitaxel-eluting stents that were used in SYNTAX. 41 Finally, PCI in the SYNTAX trial did not incorporate routine use of physiological guidance, a technique that has recently been shown both to improve clinical outcomes and to lower long-term costs compared with angiographic guidance. 42, 43 Future trials comparing physiologically guided PCI and CABG will be required to determine the overall cost-effectiveness of this strategy.
Conclusions
On the basis of the results of the SYNTAX trial, for most patients with 3-vessel or left main CAD without recent MI, CABG is a clinically and economically attractive revascularization strategy compared with DES-PCI. However, among patients with less complex disease, DES-PCI may be preferred on both clinical and economic grounds. These findings provide additional support for existing guidelines and underscore the importance of ongoing studies to define the optimal revascularization strategy for patients with left main disease.
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CLINICAL PERSPECTIVE
Coronary revascularization by either coronary artery bypass graft surgery (CABG) or percutaneous coronary revascularization (PCI) is 1 of the most frequently performed and costly procedures, with direct costs in excess of $12 billion per year in the United States alone. To better understand the relative cost-effectiveness of contemporary PCI versus CABG for patients with complex coronary artery disease from the perspective of the US healthcare system, we describe the results of a prospectively designed health economic study performed alongside the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. The main result of the study was that bypass surgery was substantially more costly in the short run and remained so at 5 years. Nevertheless, owing to differences in survival and other nonfatal events, for average patients with 3-vessel or left main coronary artery disease, CABG was economically attractive compared with PCI over a lifetime perspective. However, the cost-effectiveness of CABG differed substantially according to the level of angiographic complexity. Most notably, in patients with left main disease or less complex disease (SYNTAX score ≤22) PCI with drug-eluting stents was found to be economically dominant compared with CABG (ie, associated with lower cost and better outcomes). These findings suggest that for most patients with 3-vessel or left main coronary artery disease, CABG is not only clinically but also economically attractive compared with PCI with drug-eluting stents. However, among patients with less complex disease, PCI with drug-eluting stents may be preferred on both clinical and economic grounds. These results provide additional support for existing guidelines, adding an economic perspective on coronary revascularization in a world in which rising healthcare expenditures increasingly necessitate judicious allocation of scarce resources.
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